IINN
Inspira Technologies Oxy B.H.N. Ltd.
Medical - Devices
Market Cap$11M
5Y Perf.-88.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
IINN vs SPRO
Revenue, margins, valuation, and 5-year total return — side by side.
SPRO
Spero Therapeutics, Inc.
Biotechnology
Market Cap$141M
5Y Perf.-81.2%
IINN vs SPRO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | IINN | SPRO |
|---|---|---|
| Industry | Medical - Devices | Biotechnology |
| Market Cap | $11M | $141M |
| Revenue (TTM) | $289K | $36M |
| Net Income (TTM) | $-13M | $-44M |
| Gross Margin | 0.7% | -202.6% |
| Operating Margin | 45.1% | -130.9% |
| Forward P/E | — | 3.7x |
| Total Debt | $3M | $4M |
| Cash & Equiv. | $5M | $53M |
IINN vs SPRO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IINN
SPRO
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Inspira Technologie… (IINN) | 100 | 11.5 | -88.5% |
| Spero Therapeutics,… (SPRO) | 100 | 18.8 | -81.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IINN vs SPRO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SPRO leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Inspira Technologies Oxy B.H.N. Ltd. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
IINN
Inspira Technologies Oxy B.H.N. Ltd.
The Growth Play
IINN is the clearest fit if your priority is growth exposure.
- EPS growth 99.9%
- -16.1% revenue growth vs SPRO's -53.8%
Best for: growth exposure
SPRO
Spero Therapeutics, Inc.
The Income Pick
SPRO carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.90
- -78.2% 10Y total return vs IINN's -90.5%
- Lower volatility, beta 0.90, Low D/E 9.3%, current ratio 2.19x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IINN | -16.1% revenue growth vs SPRO's -53.8% |
| Quality / Margins | SPRO | -122.6% margin vs IINN's -43.7% |
| Stability / Safety | SPRO | Beta 0.90 vs IINN's 1.52, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SPRO | +334.3% vs IINN's -16.3% |
| Efficiency (ROA) | SPRO | -80.9% ROA vs IINN's -275.8%, ROIC -327.2% vs 0.5% |
IINN vs SPRO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
IINN vs SPRO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSPROLAGGINGIINN
IINNInspira Technologies …
1leads
SPROSpero Therapeutics, I…
3leads
6 Total Categories
CATEGORYLEADERvs IINNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
IINN2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SPRO4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
SPRO6/6
Risk & VolatilityBeta, volatility, and downside exposure
SPRO2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — IINN and SPRO each lead in 2 of 4 comparable metrics.
Income & Cash Flow (Last 12 Months)
SPRO is the larger business by revenue, generating $36M annually — 123.8x IINN's $289,000. Profitability is closely matched — net margins range from -122.6% (SPRO) to -43.7% (IINN).
| Metric | IINNInspira Technolog… | SPROSpero Therapeutic… |
|---|---|---|
| RevenueTrailing 12 months | $289,000 | $36M |
| EBITDAEarnings before interest/tax | $13M | -$45M |
| Net IncomeAfter-tax profit | -$13M | -$44M |
| Free Cash FlowCash after capex | $0 | -$28M |
| Gross MarginGross profit ÷ Revenue | +0.7% | -2.0% |
| Operating MarginEBIT ÷ Revenue | +45.1% | -130.9% |
| Net MarginNet income ÷ Revenue | -43.7% | -122.6% |
| FCF MarginFCF ÷ Revenue | — | -77.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -77.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +36.8% | +59.4% |
Evenly matched — IINN and SPRO each lead in 2 of 4 comparable metrics.
Valuation Metrics
IINN leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | IINNInspira Technolog… | SPROSpero Therapeutic… |
|---|---|---|
| Market CapShares × price | $11M | $141M |
| Enterprise ValueMkt cap + debt − cash | $8M | $93M |
| Trailing P/EPrice ÷ TTM EPS | -750.00x | -1.98x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 3.75x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 726.48x | — |
| Price / SalesMarket cap ÷ Revenue | — | 2.95x |
| Price / BookPrice ÷ Book value/share | 1.93x | 2.94x |
| Price / FCFMarket cap ÷ FCF | — | — |
IINN leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
SPRO leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
SPRO delivers a -165.5% return on equity — every $100 of shareholder capital generates $-165 in annual profit, vs $-4 for IINN. SPRO carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to IINN's 0.58x.
| Metric | IINNInspira Technolog… | SPROSpero Therapeutic… |
|---|---|---|
| ROE (TTM)Return on equity | -3.7% | -165.5% |
| ROA (TTM)Return on assets | -2.8% | -80.9% |
| ROICReturn on invested capital | +0.5% | -3.3% |
| ROCEReturn on capital employed | +0.2% | -71.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 1 |
| Debt / EquityFinancial leverage | 0.58x | 0.09x |
| Net DebtTotal debt minus cash | -$3M | -$49M |
| Cash & Equiv.Liquid assets | $5M | $53M |
| Total DebtShort + long-term debt | $3M | $4M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
SPRO leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
SPRO leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SPRO five years ago would be worth $1,870 today (with dividends reinvested), compared to $947 for IINN. Over the past 12 months, SPRO leads with a +334.3% total return vs IINN's -16.3%. The 3-year compound annual growth rate (CAGR) favors SPRO at 9.7% vs IINN's -31.8% — a key indicator of consistent wealth creation.
| Metric | IINNInspira Technolog… | SPROSpero Therapeutic… |
|---|---|---|
| YTD ReturnYear-to-date | -51.1% | +6.8% |
| 1-Year ReturnPast 12 months | -16.3% | +334.3% |
| 3-Year ReturnCumulative with dividends | -68.3% | +32.1% |
| 5-Year ReturnCumulative with dividends | -90.5% | -81.3% |
| 10-Year ReturnCumulative with dividends | -90.5% | -78.2% |
| CAGR (3Y)Annualised 3-year return | -31.8% | +9.7% |
SPRO leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
SPRO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SPRO is the less volatile stock with a 0.90 beta — it tends to amplify market swings less than IINN's 1.52 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SPRO currently trades 78.0% from its 52-week high vs IINN's 27.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IINNInspira Technolog… | SPROSpero Therapeutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.52x | 0.90x |
| 52-Week HighHighest price in past year | $1.65 | $3.22 |
| 52-Week LowLowest price in past year | $0.34 | $0.57 |
| % of 52W HighCurrent price vs 52-week peak | +27.3% | +78.0% |
| RSI (14)Momentum oscillator 0–100 | 40.9 | 46.6 |
| Avg Volume (50D)Average daily shares traded | 292K | 384K |
SPRO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | IINNInspira Technolog… | SPROSpero Therapeutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SPRO leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). IINN leads in 1 (Valuation Metrics). 1 tied.
Best OverallSpero Therapeutics, Inc. (SPRO)Leads 3 of 6 categories
Loading custom metrics...
IINN vs SPRO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is IINN or SPRO a better buy right now?
Analysts rate Spero Therapeutics, Inc.
(SPRO) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IINN or SPRO?
Over the past 5 years, Spero Therapeutics, Inc.
(SPRO) delivered a total return of -81. 3%, compared to -90. 5% for Inspira Technologies Oxy B. H. N. Ltd. (IINN). Over 10 years, the gap is even starker: SPRO returned -78. 2% versus IINN's -90. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IINN or SPRO?
By beta (market sensitivity over 5 years), Spero Therapeutics, Inc.
(SPRO) is the lower-risk stock at 0. 90β versus Inspira Technologies Oxy B. H. N. Ltd. 's 1. 52β — meaning IINN is approximately 68% more volatile than SPRO relative to the S&P 500. On balance sheet safety, Spero Therapeutics, Inc. (SPRO) carries a lower debt/equity ratio of 9% versus 58% for Inspira Technologies Oxy B. H. N. Ltd. — giving it more financial flexibility in a downturn.
04Which is growing faster — IINN or SPRO?
On earnings-per-share growth, the picture is similar: Inspira Technologies Oxy B.
H. N. Ltd. grew EPS 99. 9% year-over-year, compared to -395. 3% for Spero Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — IINN or SPRO?
Spero Therapeutics, Inc.
(SPRO) is the more profitable company, earning -142. 9% net margin versus -43. 7% for Inspira Technologies Oxy B. H. N. Ltd. — meaning it keeps -142. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IINN leads at 45. 1% versus -152. 9% for SPRO. At the gross margin level — before operating expenses — IINN leads at 0. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — IINN or SPRO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is IINN or SPRO better for a retirement portfolio?
For long-horizon retirement investors, Spero Therapeutics, Inc.
(SPRO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90)). Inspira Technologies Oxy B. H. N. Ltd. (IINN) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SPRO: -78. 2%, IINN: -90. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between IINN and SPRO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.